Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression Meeting Abstract


Authors: Rosenberg, J.; Necchi, A.; Sweis, R. F.; Nakajima, K.; Lu, C.; Nogai, H.
Abstract Title: Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
Meeting Title: 43rd ESMO Congress (ESMO 2018)
Journal Title: Annals of Oncology
Volume: 29
Issue: Suppl. 8
Meeting Dates: 2018 Oct 19-23
Meeting Location: Munich, Germany
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2018-10-01
Start Page: mdy283.134
Language: English
ACCESSION: WOS:000459277302108
PROVIDER: wos
DOI: 10.1093/annonc/mdy283.134
Notes: Meeting Abstract: 925TiP -- Appears on page viii329 of the abstract book -- Source: Wos
Altmetric Score
MSK Authors
  1. Jonathan Eric Rosenberg
    225 Rosenberg